New drug combo shows promise for myeloma patients ineligible for transplant

NCT ID NCT03984097

Completed Disease control Sponsor: Takeda Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This phase 1b trial tested the safety of adding TAK-079 (Mezagitamab) to standard treatments for 50 people newly diagnosed with multiple myeloma who cannot have a stem cell transplant. The goal was to find the right dose and watch for side effects. Researchers also tracked how well the cancer responded to treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TAK-079 (also called Mezagitamab) combined with lenalidomide, dexamethasone, bortezomib, or pomalidomide
What this could lead to: If successful, this could help determine a safe dose of TAK-079 for treating multiple myeloma, potentially improving disease control when used with standard therapies.
What could go wrong: This is an early-phase trial with only 50 participants, so results may not apply to all patients. Side effects from the drug combination are possible, and the study focuses on safety, not effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma plasma cell neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

Alabama Oncology

Birmingham, Alabama, 35211, United States
American Oncology Partners of Maryland, PA

Bethesda, Maryland, 20817, United States
Columbia University Medical Center

New York, New York, 10032, United States
Froedtert Hospital & the Medical College of Wisconsin

Milwaukee, Wisconsin, 53226, United States
Good Samaritan Hospital

Cincinnati, Ohio, 45220, United States
Levine Cancer Institute

Charlotte, North Carolina, 28204, United States
MD Anderson Cancer Center

Houston, Texas, 77030, United States
Oregon Health & Science University

Portland, Oregon, 97239, United States
Pacific Cancer Care

Monterey, California, 93940, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.